Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK
Int Health. 2014 Dec;6(4):269-70. doi: 10.1093/inthealth/ihu045. Epub 2014 Jul 6.
A review of the clinical manifestations of sickle cell disease (SCD), available therapeutic interventions and a necessarily limited assessment of progress with their implementation in Nigeria (the country with the largest number of affected individuals worldwide) was recently published in this journal. Despite a disappointing dearth of targeted therapy for a condition whose molecular basis has been well understood for half a century, there is a wealth of evidence-based supportive interventions, including antibiotic and vaccination prophylaxis against early bacteraemic mortality, childhood stroke risk prevention, patient and population education and screening and community care provision that are simple and inexpensive to implement. There is a real opportunity for international collaboration to drive an improvement in healthcare provision for this condition.
最近在本刊发表了一篇关于镰状细胞病(SCD)临床表现、现有治疗干预措施的综述,以及对这些干预措施在尼日利亚(全球受影响人数最多的国家)实施情况的有限评估。尽管针对这种分子基础已被了解了半个世纪的疾病,靶向治疗令人失望地缺乏,但仍有大量基于证据的支持性干预措施,包括针对早期菌血症死亡率的抗生素和疫苗预防、儿童中风风险预防、患者和人群教育以及筛查和社区护理提供,这些措施简单且廉价。国际合作确实有机会改善这种疾病的医疗服务。